News
GNNSF
2.120
NaN%
--
Weekly Report: what happened at GNNSF last week (1215-1219)?
Weekly Report · 5d ago
Tech Voices: DOD's Chinese military firm list, Cerebras eyes Q2 IPO
Seeking Alpha · 12/19 21:41
Genscript Biotech Grants Share Awards to Directors
TipRanks · 12/15 23:39
Genscript Biotech Updates RSU Schemes for Improved Governance
TipRanks · 12/15 23:14
Weekly Report: what happened at GNNSF last week (1208-1212)?
Weekly Report · 12/15 10:29
Weekly Report: what happened at GNNSF last week (1201-1205)?
Weekly Report · 12/08 10:28
Legend Biotech Unveils Promising Data at 2025 ASH Meeting
TipRanks · 12/07 11:07
Weekly Report: what happened at GNNSF last week (1124-1128)?
Weekly Report · 12/01 10:23
Weekly Report: what happened at GNNSF last week (1117-1121)?
Weekly Report · 11/24 10:28
Guotai Haitong Sticks to Its Buy Rating for Genscript Biotech (GNNSF)
TipRanks · 11/22 05:05
Weekly Report: what happened at GNNSF last week (1110-1114)?
Weekly Report · 11/17 10:29
Huatai Securities Reaffirms Their Buy Rating on Genscript Biotech (GNNSF)
TipRanks · 11/15 05:06
Genscript Biotech Announces Q3 2025 Results for Legend Biotech
TipRanks · 11/12 12:42
Weekly Report: what happened at GNNSF last week (1103-1107)?
Weekly Report · 11/10 10:26
Genscript Biotech’s Associate to Present New Data at Hematology Meeting
TipRanks · 11/03 23:41
Weekly Report: what happened at GNNSF last week (1027-1031)?
Weekly Report · 11/03 10:26
Weekly Report: what happened at GNNSF last week (1020-1024)?
Weekly Report · 10/27 10:29
Weekly Report: what happened at GNNSF last week (1013-1017)?
Weekly Report · 10/20 10:26
Genscript Biotech’s ProBio Receives Significant Sublicense Revenue Boost
Barchart · 10/15 04:50
Genscript Biotech Reports Strong CARVYKTI® Sales in Q3 2025
TipRanks · 10/14 12:38
More
Webull provides a variety of real-time GNNSF stock news. You can receive the latest news about Genscript Biotec through multiple platforms. This information may help you make smarter investment decisions.
About GNNSF
Genscript Biotech Corp is an investment holding company principally engaged in the manufacture and sale of life science research products and services. The Company operates its businesses through five segments. The Life-science Services and Products segment provides comprehensive research services and products. The Biologics Development Services segment provides comprehensive services to help biopharmaceutical and biotech companies accelerate the development of therapeutic antibodies, and gene, cell therapy products with an integrated platform. The Industrial Synthetic Biology Products segment provides industrial enzyme development and production through non-pathogenic microbial strains constructed using genetic engineering. The Cell Therapy segment discovers and develops CAR-T therapies for the treatment of liquid and solid tumors. The Operation segment provides shared services to other segments. The Company mainly operates its businesses in the domestic and overseas markets.